Should I buy or sell Century Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks .

What is Century Therapeutics' stock price target for 2024?

6 analysts have issued 12-month price targets for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $20.00. On average, they expect the company's stock price to reach $13.57 in the next twelve months. This suggests a possible upside of 759.0% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts .

How have IPSC shares performed in 2023?

Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC shares have decreased by 69.2% and is now trading at $1.58. View the best growth stocks for 2023 here .

Are investors shorting Century Therapeutics?

Century Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 742,600 shares, a decrease of 11.9% from the October 31st total of 842,900 shares. Based on an average daily volume of 128,900 shares, the days-to-cover ratio is presently 5.8 days. Approximately 3.1% of the company's stock are short sold. View Century Therapeutics' Short Interest .

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our IPSC earnings forecast .

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The business had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.08 million. Century Therapeutics had a negative trailing twelve-month return on equity of 49.28% and a negative net margin of 5,183.16%.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.56%), Avidity Partners Management LP (1.84%), Jacobs Levy Equity Management Inc. (0.29%), Charles Schwab Investment Management Inc. (0.25%), New York Life Investment Management LLC (0.17%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Eli Casdin , Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends .

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Century Therapeutics Stock Price, News & Analysis (NASDAQ:IPSC)

$1.71

+0.13 (+8.23%)

(As of 10:01 AM ET)

Compare

Today's Range: $1.60
▼
$1.75
50-Day Range: $1.28
▼
$2.02
52-Week Range: $1.28
▼
$9.71

Volume: 302,626 shs
Average Volume: 136,682 shs
Market Capitalization: $102.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.57

Century Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 748.2% Upside
$13.57 Price Target
Short Interest: Healthy
3.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.75
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.08) to ($2.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

349th out of 948 stocks

Biological Products, Except Diagnostic Industry

52nd out of 147 stocks

3.4

Analyst's Opinion

Consensus Rating
Century Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.57, Century Therapeutics has a forecasted upside of 748.2% from its current price of $1.60.
Amount of Analyst Coverage
Century Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.06% of the float of Century Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Century Therapeutics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Century Therapeutics has recently decreased by 11.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Century Therapeutics does not currently pay a dividend.
Dividend Growth
Century Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPSC.

3.2

News and Social Media Coverage

News Sentiment
Century Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Century Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Century Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Century Therapeutics is held by insiders.
Percentage Held by Institutions
Only 32.28% of the stock of Century Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Century Therapeutics are expected to grow in the coming year, from ($2.08) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Century Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Century Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Century Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Century Therapeutics Stock (NASDAQ:IPSC)

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPSC Stock News Headlines

December 6, 2023 | markets.businessinsider.com

Century Therapeutics Announces IND Application Clearance For CNTY-101

December 6, 2023 | msn.com

Century Therapeutics stock gains after IND clearance for lupus candidate

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 6, 2023 | finance.yahoo.com

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

December 6, 2023 | finance.yahoo.com

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

December 4, 2023 | americanbankingnews.com

Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decline in Short Interest

November 21, 2023 | finance.yahoo.com

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

November 15, 2023 | markets.businessinsider.com

Promising Future for Century Therapeutics: Analyzing Daina Graybosch’s Buy Rating Amid Key Clinical Trials and Corporate Developments

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | finance.yahoo.com

FMR LLC Adjusts Position in Century Therapeutics Inc

November 12, 2023 | markets.businessinsider.com

Century Therapeutics: Strengthened Leadership, Solid Financials and Promising Clinical Trials Drive Buy Recommendation

November 10, 2023 | markets.businessinsider.com

William Blair Reaffirms Their Hold Rating on Century Therapeutics (IPSC)

November 9, 2023 | benzinga.com

Recap: Century Therapeutics Q3 Earnings

November 9, 2023 | finance.yahoo.com

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

November 9, 2023 | finance.yahoo.com

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 9, 2023 | finance.yahoo.com

Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results

November 7, 2023 | markets.businessinsider.com

Century Therapeutics’ Stock Buy Rating: Anchored on Promising Clinical Data, Solid Financials, and Innovative AlloEvasion Technology

November 2, 2023 | finance.yahoo.com

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition

October 21, 2023 | finance.yahoo.com

Can Century Therapeutics (NASDAQ:IPSC) Afford To Invest In Growth?

September 26, 2023 | finance.yahoo.com

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

September 10, 2023 | thestreet.com

Century Therapeutics Inc.

August 29, 2023 | msn.com

JP Morgan Downgrades Century Therapeutics (IPSC)

August 28, 2023 | msn.com

JP Morgan cuts Century Therapeutics to neutral, cites lengthy data timeline

August 11, 2023 | msn.com

Piper Sandler Maintains Century Therapeutics (IPSC) Overweight Recommendation

August 11, 2023 | msn.com

EF Hutton Reiterates Century Therapeutics (IPSC) Buy Recommendation

August 10, 2023 | msn.com

Chardan Capital Maintains Century Therapeutics (IPSC) Buy Recommendation

August 10, 2023 | msn.com

HC Wainwright & Co. Maintains Century Therapeutics (IPSC) Buy Recommendation

See More Headlines

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IPSC
CUSIP: N/A
CIK: 1850119
Web: www.centurytx.com
Phone: 267-817-5790
Fax: N/A
Employees: 163
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.57
High Stock Price Target: $20.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +759.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-130,930,000.00
Net Margins: -5,183.16%
Pretax Margin: -5,071.34%
Return on Equity: -49.28%
Return on Assets: -29.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.50
Quick Ratio: 8.50

Sales & Book Value

Annual Sales: $2.49 million
Price / Sales: 38.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.13 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 59,835,000
Free Float: 55,288,000
Market Cap: $94.54 million
Optionable: Not Optionable
Beta: 0.67

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Michael C. Diem M.D. (Age 52)
Chief Financial Officer
Comp: $650.66k
Dr. Adrienne Farid Ph.D. (Age 61)
COO & Head of Early Development
Comp: $650.66k
Dr. Gregory Russotti Ph.D. (Age 56)
Interim President & CEO
Mr. Kenneth J. Dow J.D.
Senior VP of General Counsel
Dr. Shane Williams Ph.D.
Chief People Officer
Dr. Hyam I. Levitsky M.D. (Age 65)
President of Research & Development
Comp: $502.12k
Michael Naso Ph.D.
Senior VP of Cell Engineering
Mr. Douglas Carr CPA
Senior VP of Finance & Operations and Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IPSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.
What is Century Therapeutics' stock price target for 2024?: 6 analysts have issued 12-month price targets for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $20.00. On average, they expect the company's stock price to reach $13.57 in the next twelve months. This suggests a possible upside of 759.0% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.
How have IPSC shares performed in 2023?: Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC shares have decreased by 69.2% and is now trading at $1.58.
View the best growth stocks for 2023 here.
Are investors shorting Century Therapeutics?: Century Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 742,600 shares, a decrease of 11.9% from the October 31st total of 842,900 shares. Based on an average daily volume of 128,900 shares, the days-to-cover ratio is presently 5.8 days. Approximately 3.1% of the company's stock are short sold.
View Century Therapeutics' Short Interest.
When is Century Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our IPSC earnings forecast.

How were Century Therapeutics' earnings last quarter?: Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The business had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.08 million. Century Therapeutics had a negative trailing twelve-month return on equity of 49.28% and a negative net margin of 5,183.16%.
When did Century Therapeutics IPO?: (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.
Who are Century Therapeutics' major shareholders?: Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.56%), Avidity Partners Management LP (1.84%), Jacobs Levy Equity Management Inc. (0.29%), Charles Schwab Investment Management Inc. (0.25%), New York Life Investment Management LLC (0.17%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends.
How do I buy shares of Century Therapeutics?: Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IPSC) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Century Therapeutics Stock Price, News & Analysis (NASDAQ:IPSC)

Century Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Century Therapeutics Stock (NASDAQ:IPSC)

IPSC Stock Price History

IPSC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IPSC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™